Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

Author： Güth Uwe

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.129, Iss.3, 2011-10, pp. : 799-807

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Breast self-examination: who teaches it, who is taught, and how often? (United States)

By Nekhlyudov L.

Cancer Causes and Control, Vol. 13, Iss. 4, 2002-05 ,pp. : 343-351

Springer Publishing Company

Access to resources Recommend Favorite

Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?

By Cheung K.L.

Breast Cancer Research and Treatment, Vol. 65, Iss. 2, 2001-01 ,pp. : 155-162

Springer Publishing Company

Access to resources Recommend Favorite

Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment

By Niikura Naoki

Breast Cancer, Vol. 20, Iss. 1, 2013-01 ,pp. : 67-74

Springer Publishing Company

Access to resources Recommend Favorite

Residual Breast Tissue after Mastectomy: How Often and Where Is It Located?

By Griepsma M. Roy van Zuidewijn D. Grond A. Siesling S. Groen H. Bock G.

Annals of Surgical Oncology, Vol. 21, Iss. 4, 2014-04 ,pp. : 1260-1266

Springer Publishing Company

Access to resources Recommend Favorite

Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?

By Alkan Ali

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1430-1430

Humana Press, Inc

Access to resources Recommend Favorite